Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819732 | 0.86 | ALDH1A1 (0.32) | ALDH1A1LMNA | |
| SCHEMBL2819826 | 0.84 | ALDH1A1 (0.33) | ALDH1A1LMNA | |
| SCHEMBL2822349 | 0.83 | ALDH1A1 (0.30) | ALDH1A1LMNA | |
| SCHEMBL2822638 | 0.83 | ALDH1A1 (0.30) | ALDH1A1LMNA | |
| SCHEMBL2819899 | 0.82 | — | — | |
| SCHEMBL2821975 | 0.82 | — | — | |
| SCHEMBL2819668 | 0.82 | — | — | |
| SCHEMBL2820451 | 0.82 | RET (0.32) | — | |
| SCHEMBL2823286 | 0.80 | JAK2 (0.30) | — | |
| SCHEMBL2821976 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795447-B2 | 4-(Acylaminoacetylamino)imidazole derivatives, e.g., methyl 3-(4-{2-[2-(3,5-Difluorophenyl)acetylamino]pentanoylamino}imidazol-1-yl)butyrate; treating neurodegenerative and/or neurological disorders such as Alzheimer's disease and Down's Syndrome | PFIZER INC (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100168107-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC (US) | 2010-07-01 | — | — | US | disclosed |
| US-20080227781-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2008-09-18 | — | — | US | disclosed |
| EP-1730119-B1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2008-06-25 | — | — | EP | disclosed |
| US-7342118-B2 | Imidazole compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168107-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | APP, PSEN1, PSEN2 | ALDH1A1 1117/4885LMNA 3120/4885 |
| US-20080227781-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | APP, PSEN1, PSEN2 | ALDH1A1 1117/4885LMNA 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.